Vidipha Central Pharmaceutical JSC

Vidipha Central Pharmaceutical JSC maintains a capital structure with a debt-to-equity ratio of 0.46, indicating a relatively balanced approach to financing. The company's liquidity position is characterized by a current ratio of 1.88, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the operating cash flow is negative at -45,371,111,060 VND, which may raise concerns about its ability to fund operations without external financing.

In terms of profitability, the company's return on equity is 2.19%, and its return on assets is 1.38%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. The net income of 15,636,023,630 VND reflects a modest profit margin, which may indicate challenges in maintaining high gross margins or managing operating expenses.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risks if market conditions in its primary operating region deteriorate.

The growth trajectory of Vidipha Central Pharmaceutical JSC is not clearly defined in the available data, as there are no specific projections or historical revenue growth rates provided. The company's capital expenditure of -9,661,141,460 VND suggests a reduction in investment in new projects or facilities, which could impact future growth.

The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's free cash flow of 39,339,987,850 VND provides some flexibility, but the negative net cash position after subtracting total debt may necessitate careful management of cash reserves.

Recent events, such as the latest actual revenue of 421,548,211,000 VND, suggest that the company is performing in line with analyst estimates. However, the absence of detailed filings or transcripts limits the ability to assess the company's strategic direction and operational performance in greater depth.

Net margin of 7.0% outperforms the industry median of 3.9%, demonstrating strong bottom-line profitability relative to peers.

Free cash flow surged 78.8% year-over-year, reflecting a substantial improvement in cash generation capabilities.

Revenue CAGR of -1.3% over four years shows relative stability compared to the volatile net income growth.

Capital expenditure intensity is lower than the cohort median, suggesting efficient capital allocation relative to peers.

High credit risk flag signals significant potential for financial distress or default issues within the company.

Cash conversion ratio sits in the bottom quartile of the cohort, indicating poor efficiency in turning sales into cash.

Revenue VND 985.64B, +5,5% YoY; Operating income −0,6% YoY.

• ▍Revenue VND 985.64B, +5,5% YoY
• ▍Operating income −0,6% YoY
• ▍Net income −11,2% YoY
• ▍Free cash flow −57,9% YoY
• ▍Net margin 6.5%